Active, not recruitingPhase 1NCT03173976
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
Studying Chondrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mohammed Milhem
- Principal Investigator
- Mohammed Milhem, MBBSUniversity of Iowa
- Intervention
- Zoledronic Acid(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2028
Study locations (1)
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Collaborators
Rising Tide Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03173976 on ClinicalTrials.govOther trials for Chondrosarcoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGNANCT07360964Clear Cell Chondrosarcoma in ItalyIstituto Ortopedico Rizzoli
- RECRUITINGNCT07315542Diagnostic and Therapeutic Targets in Cartilaginous TumoursSt. Anne's University Hospital Brno, Czech Republic
- RECRUITINGEARLY PHASE1NCT06645808PET-imaging of Two Vartumabs in Patients With Solid TumorsVar2 Pharmaceuticals
- RECRUITINGPHASE3NCT06127407Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment RegimenServier Bio-Innovation LLC
- RECRUITINGNCT06486506Proximal Femur Reconstruction Following Resection of Primary Bone Tumors: Analysis of the Clinical and Radiographic ResultsCostantino Errani
- RECRUITINGPHASE2NCT06176989Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsNational Cancer Institute (NCI)
- RECRUITINGNANCT06387485A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative PlanningRicoh USA, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT05836571Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaNational Cancer Institute LAO